{"title":"土耳其皮肤黑色素瘤患者年龄相关性生存率下降:回顾性分析","authors":"Faruk Tas, Kayhan Erturk","doi":"10.5826/dpc.1502a4936","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In cancer patients, the age of a patient at the time of diagnosis is considered among the important clinical indicators.</p><p><strong>Objectives: </strong>We aimed to investigate this significance in melanoma patients by creating patient age groups.</p><p><strong>Methods: </strong>A total of 1,496 adult skin melanoma patients were evaluated retrospectively. Patients were divided into six age groups: under 30 (<30), 31-39 (30s), 40-49 (40s), 50-59 (50s), 60-69 (60s), and 70 and older (70+).</p><p><strong>Results: </strong>The median age was 52 years (range 16-104), and the most common age group was the 50s (n=340, 22.7%). As age increased, so did the Clark level (P=0.0001), the rate of ulceration (P=0.0001), and the rate of BRAF wild-type (P=0.002). The recurrence rates of early-stage patients were similar for all age groups. A significant overall survival (OS) advantage was found only between the following age groups: <30 and 60s (P=0.04) and <30 and 70+ (P=0.01). Five-year OS were, from young to old: 70.5%, 66%, 63.1%, 66.3%, 57.2%, and 46.8%. A significant OS advantage was found only between the following age groups: <30 and 60s (P=0.04) and <30 and 70+ (P=0.01). The 70+ group had significantly worse OS rates in all age groups (<30: P=0.0001; 30s P=0.0001; 40s: P= 0.001; 50s: P=0.0001; and 60s: P=0.04).</p><p><strong>Conclusion: </strong>While some unfavorable histopathological prognostic factors are associated more frequently with increasing age, clinical stage and recurrence do not differ significantly between age groups. A possible explanation for this might be that the elderly have more comorbidities and die of different causes.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 2","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090967/pdf/","citationCount":"0","resultStr":"{\"title\":\"Age-related Survival Declines in Turkish Patients with Cutaneous Melanoma: A Retrospective Analysis.\",\"authors\":\"Faruk Tas, Kayhan Erturk\",\"doi\":\"10.5826/dpc.1502a4936\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In cancer patients, the age of a patient at the time of diagnosis is considered among the important clinical indicators.</p><p><strong>Objectives: </strong>We aimed to investigate this significance in melanoma patients by creating patient age groups.</p><p><strong>Methods: </strong>A total of 1,496 adult skin melanoma patients were evaluated retrospectively. Patients were divided into six age groups: under 30 (<30), 31-39 (30s), 40-49 (40s), 50-59 (50s), 60-69 (60s), and 70 and older (70+).</p><p><strong>Results: </strong>The median age was 52 years (range 16-104), and the most common age group was the 50s (n=340, 22.7%). As age increased, so did the Clark level (P=0.0001), the rate of ulceration (P=0.0001), and the rate of BRAF wild-type (P=0.002). The recurrence rates of early-stage patients were similar for all age groups. A significant overall survival (OS) advantage was found only between the following age groups: <30 and 60s (P=0.04) and <30 and 70+ (P=0.01). Five-year OS were, from young to old: 70.5%, 66%, 63.1%, 66.3%, 57.2%, and 46.8%. A significant OS advantage was found only between the following age groups: <30 and 60s (P=0.04) and <30 and 70+ (P=0.01). The 70+ group had significantly worse OS rates in all age groups (<30: P=0.0001; 30s P=0.0001; 40s: P= 0.001; 50s: P=0.0001; and 60s: P=0.04).</p><p><strong>Conclusion: </strong>While some unfavorable histopathological prognostic factors are associated more frequently with increasing age, clinical stage and recurrence do not differ significantly between age groups. A possible explanation for this might be that the elderly have more comorbidities and die of different causes.</p>\",\"PeriodicalId\":11168,\"journal\":{\"name\":\"Dermatology practical & conceptual\",\"volume\":\"15 2\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090967/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology practical & conceptual\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5826/dpc.1502a4936\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology practical & conceptual","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5826/dpc.1502a4936","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Age-related Survival Declines in Turkish Patients with Cutaneous Melanoma: A Retrospective Analysis.
Introduction: In cancer patients, the age of a patient at the time of diagnosis is considered among the important clinical indicators.
Objectives: We aimed to investigate this significance in melanoma patients by creating patient age groups.
Methods: A total of 1,496 adult skin melanoma patients were evaluated retrospectively. Patients were divided into six age groups: under 30 (<30), 31-39 (30s), 40-49 (40s), 50-59 (50s), 60-69 (60s), and 70 and older (70+).
Results: The median age was 52 years (range 16-104), and the most common age group was the 50s (n=340, 22.7%). As age increased, so did the Clark level (P=0.0001), the rate of ulceration (P=0.0001), and the rate of BRAF wild-type (P=0.002). The recurrence rates of early-stage patients were similar for all age groups. A significant overall survival (OS) advantage was found only between the following age groups: <30 and 60s (P=0.04) and <30 and 70+ (P=0.01). Five-year OS were, from young to old: 70.5%, 66%, 63.1%, 66.3%, 57.2%, and 46.8%. A significant OS advantage was found only between the following age groups: <30 and 60s (P=0.04) and <30 and 70+ (P=0.01). The 70+ group had significantly worse OS rates in all age groups (<30: P=0.0001; 30s P=0.0001; 40s: P= 0.001; 50s: P=0.0001; and 60s: P=0.04).
Conclusion: While some unfavorable histopathological prognostic factors are associated more frequently with increasing age, clinical stage and recurrence do not differ significantly between age groups. A possible explanation for this might be that the elderly have more comorbidities and die of different causes.